Shaw, D M <br/><br/>
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.  [electronic resource] 

 -  British journal of cancer  Feb 2007 
 - 567-74 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0007-0920 
<br/><br/><label>Standard No.: </label>10.1038/sj.bjc.6603567  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antigens, Neoplasm--immunology<br/>Carcinoma, Renal Cell--diagnosis<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Drug-Related Side Effects and Adverse Reactions<br/>Enterotoxins--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Injections, Intravenous<br/>Interleukin-2--biosynthesis<br/>Kidney Neoplasms--diagnosis<br/>Male<br/>Membrane Glycoproteins--administration & dosage<br/>Middle Aged<br/>Predictive Value of Tests<br/>Prognosis<br/>Recombinant Fusion Proteins--administration & dosage<br/>Survival Rate<br/>Treatment Outcome